Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients
Phase of Trial: Phase IV
Latest Information Update: 28 Jan 2016
Price : $35 *
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms COSTAN
- Sponsors Biogen
- 31 Aug 2018 Biomarkers information updated
- 28 Jan 2016 Last checked against ClinicalTrials.gov record.
- 26 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to discontinued.